ATRA reduces the incidence of T1DM by protecting islet β-cells, upregulating the levels of the pancreatic β-cell factor IL-4, reducing the cell toxicity-associated levels of IFN-γ in β-cells, and maintaining the Th1/Th2 balance3. The gene discussed is IL4; the disease is type 1 diabetes mellitus.